Take NO for an answer
Nature Medicine
November 14, 2011
Treatments that raise nitric oxide levels could be useful for treating a congenital metabolic disease, argininosuccinic aciduria (ASA), reports a study published online this week in Nature Medicine.
The enzyme that is defective in individuals with ASA, argininosuccinate lyase (ASL), generates the amino acid arginine, which is then used to make both nitric oxide, which regulates vascular function, and urea, which is used to dispose of waste nitrogen in the liver. Surprisingly, administration of the product of the defective enzyme, arginine, is not fully effective in treating individuals with ASA.
Based on studies in both a newly-generated mouse model of ASA and individuals with ASA, Brendan Lee and his colleagues found that the answer to this paradox is that ASL has an additional and unexpected role in making nitric oxide: it acts as a structural component of a multiprotein complex that converts arginine to nitric oxide. Because of ASL’s structural role, cells lacking the enzyme can’t make nitric oxide even if they are given arginine. To begin to translate these mechanistic studies into a therapy for ASA, the researchers showed that treatment of the ASA mouse model with an agent that raises nitric oxide levels, sodium nitrite, had beneficial effects on growth and survival.
doi: 10.1038/nm.2544
Research highlights
-
Aug 12
Ageing: Mutations in the ageing human heart identifiedNature Aging
-
Aug 12
Palaeontology: T. rex and relatives traded big eyes for bigger bitesCommunications Biology
-
Aug 10
Epidemiology: Estimating the risk of SARS-related coronaviruses from bats in Southeast AsiaNature Communications
-
Aug 5
Microbiology: Single switch makes Escherichia coli beneficial insect partnerNature Microbiology
-
Aug 5
Conservation: More than half of unassessable species may be at risk of extinctionCommunications Biology
-
Aug 4
Physiology: Restoring cellular functions in pigs after deathNature